Ex-Purdue exec's new immunology startup launches with $60M

The biotech plans to create drugs that target the immune system’s first line of defense, known as the innate immune system.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.